Stifel Nicolaus Forecasts Strong Price Appreciation for Insmed (NASDAQ:INSM) Stock

Key Points

• Stifel Nicolaus has raised its price target for Insmed (NASDAQ:INSM) from $121.00 to $145.00, indicating a potential upside of 14.38% from the previous close and maintaining a "buy" rating on the stock.
• Insmed reported a quarterly earnings loss of ($1.70) EPS, missing the consensus estimate, but saw an 18.9% year-over-year increase in revenue.
• Insiders have sold over 527,000 shares of Insmed stock in the last three months, while institutional investors have increased their holdings significantly, with Vanguard Group owning about 18.3 million shares.

Insmed (NASDAQ:INSM - Get Free Report) had its price objective upped by research analysts at Stifel Nicolaus from $121.00 to $145.00 in a research note issued on Thursday,Benzinga reports. The firm currently has a "buy" rating on the biopharmaceutical company's stock. Stifel Nicolaus' target price points to a potential upside of 13.46% from the stock's current price.

INSM has been the subject of a number of other reports. Bank of America raised their price target on shares of Insmed from $94.00 to $109.00 and gave the stock a "buy" rating in a report on Wednesday, June 11th. JPMorgan Chase & Co. lifted their price objective on shares of Insmed from $90.00 to $111.00 and gave the company an "overweight" rating in a report on Tuesday, July 8th. Mizuho lifted their price objective on shares of Insmed from $130.00 to $165.00 and gave the company an "outperform" rating in a report on Wednesday. UBS Group reiterated a "buy" rating and set a $133.00 price objective (up from $124.00) on shares of Insmed in a report on Friday, August 8th. Finally, The Goldman Sachs Group lifted their price objective on shares of Insmed from $114.00 to $142.00 and gave the company a "buy" rating in a report on Wednesday. One equities research analyst has rated the stock with a hold rating and fifteen have assigned a buy rating to the stock. According to MarketBeat.com, Insmed presently has an average rating of "Moderate Buy" and a consensus target price of $129.57.

Insmed Trading Up 0.0%

NASDAQ INSM traded up $0.05 during mid-day trading on Thursday, reaching $127.80. 3,528,446 shares of the stock were exchanged, compared to its average volume of 2,934,935. Insmed has a one year low of $60.40 and a one year high of $128.48. The stock has a 50 day simple moving average of $103.62 and a 200-day simple moving average of $83.92. The stock has a market cap of $27.01 billion, a P/E ratio of -22.38 and a beta of 0.95. The company has a debt-to-equity ratio of 0.45, a current ratio of 6.68 and a quick ratio of 6.33.

Insmed (NASDAQ:INSM - Get Free Report) last announced its earnings results on Thursday, August 7th. The biopharmaceutical company reported ($1.70) earnings per share for the quarter, missing analysts' consensus estimates of ($1.30) by ($0.40). Insmed had a negative return on equity of 195.37% and a negative net margin of 259.82%. The firm had revenue of $107.42 million for the quarter, compared to the consensus estimate of $104.06 million. During the same period in the prior year, the business earned ($1.94) EPS. Insmed's quarterly revenue was up 18.9% on a year-over-year basis. On average, analysts anticipate that Insmed will post -4.56 EPS for the current year.

Insider Activity at Insmed

In other news, insider Michael Alexander Smith sold 933 shares of Insmed stock in a transaction that occurred on Tuesday, July 15th. The shares were sold at an average price of $102.51, for a total transaction of $95,641.83. Following the sale, the insider owned 66,394 shares in the company, valued at $6,806,048.94. This trade represents a 1.39% decrease in their ownership of the stock. The transaction was disclosed in a filing with the SEC, which is available at the SEC website. Also, insider Orlov S. Nicole Schaeffer sold 99,172 shares of the business's stock in a transaction on Wednesday, June 11th. The stock was sold at an average price of $93.42, for a total transaction of $9,264,648.24. Following the completion of the sale, the insider owned 89,407 shares in the company, valued at $8,352,401.94. This represents a 52.59% decrease in their position. The disclosure for this sale can be found here. In the last 90 days, insiders sold 525,716 shares of company stock worth $49,665,671. 3.00% of the stock is owned by insiders.

Institutional Trading of Insmed

Large investors have recently made changes to their positions in the stock. Renaissance Technologies LLC purchased a new stake in Insmed in the fourth quarter worth about $1,746,000. Summit Investment Advisors Inc. lifted its stake in Insmed by 10.2% in the fourth quarter. Summit Investment Advisors Inc. now owns 17,551 shares of the biopharmaceutical company's stock worth $1,212,000 after acquiring an additional 1,630 shares during the period. Mariner LLC raised its holdings in Insmed by 23.4% in the fourth quarter. Mariner LLC now owns 30,788 shares of the biopharmaceutical company's stock worth $2,126,000 after purchasing an additional 5,844 shares in the last quarter. Jump Financial LLC bought a new position in Insmed in the fourth quarter worth about $230,000. Finally, Marshall Wace LLP raised its holdings in Insmed by 38.0% in the fourth quarter. Marshall Wace LLP now owns 1,064,215 shares of the biopharmaceutical company's stock worth $73,473,000 after purchasing an additional 293,004 shares in the last quarter.

About Insmed

Insmed Incorporated is a global biopharmaceutical company on a mission to transform the lives of patients with serious and rare diseases. Insmed's first commercial product is ARIKAYCE® (amikacin liposome inhalation suspension), which is approved in the United States for the treatment of Mycobacterium avium complex (MAC) lung disease as part of a combination antibacterial drug regimen for adult patients with limited or no alternative treatment options.